The long-range goal of the Moffitt Skin SPORE is to promote progress in the prevention and treatment of cutaneous malignancies based on developments in our laboratories that are applied to innovative clinical trials. The bench work in each project is a necessary precursor to carrying out the trials associated with the SPORE, since those investigations will explore new biomarkers and correlative assays that are integral to the translational importance of each trial. The translational endpoints of the trials will provide new data that will lead to further laboratory developments that in turn will iteratively lead to strategies for improved trials. The bench-to-bedside-to-bench interaction is imbedded within the core values of Moffitt as a free-standing cancer center, in which a dedicated group of clinician-investigators with extensive experience in the management of melanoma and non-melanoma skin cancer will work with an outstanding group of basic scientists to accelerate the movement of ideas out of the laboratory to the clinic. The support of the Moffitt Cancer Center and its Comprehensive Melanoma Research Center will be crucial to fulfilling this goal, providing ancillary resources and infrastructure to insure the success of the Moffitt Skin SPORE goals. In this Skin SPORE application, the melanoma projects will focus on research in melanoma biology, immunity and signaling that create opportunities to potentiate current and developing clinical approaches to the treatment of cutaneous malignancies. Project 1 will pave the way for larger randomized phase II or phase III trials of adoptive immunotherapy with tumor infiltrating lymphocytes to support the inclusion of BRAF agents with this promising therapy, based on innovative approaches for how these two modalities should be brought together. Project 2 will support the use of Hsp90 inhibitors to overcome resistance to BRAF inhibition in phase II and III trials, redefining how we look at resistance to targeted therapies. Project 3 represents a paradigm shift that employs epigenetic manipulation to alter how we use immunotherapy, and will justify phase II efficacy testing of the combination of HDAc inhibitors with ipilimumab and other immune stimulants. Project 4 will focus on Human Papilloma Virus (HPV) and Merkel's Cell Polyoma Virus (MCPV) types that could potentially play a key role in the development of non-melanoma skin cancers. We expect that data from Project 4 will justify developing new prevention trials of vaccines for HPV and MCPV to prevent squamous and/or basal cell cancers of the skin. The success of each project and the Moffitt Skin SPORE as a whole will have a major impact on the management of cutaneous malignancies.

Public Health Relevance

Moffitt Skin SPORE investigators will carry out 4 projects, each of which is based on an innovative, fundamental and scientifically exciting observation made by our own researchers and ready to be translated into phase I or II clinical trials. They will perfor important translational assays that utilize tissue from trials that prospectively assess the clinicl utility of these approaches, each of which has the potential to impact the way we conduct therapeutic and prevention interventions for patients with cutaneous malignancies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Agarwal, Rajeev K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Rebecca, Vito W; Wood, Elizabeth; Fedorenko, Inna V et al. (2014) Evaluating melanoma drug response and therapeutic escape with quantitative proteomics. Mol Cell Proteomics 13:1844-54
Kim, Sungjune; Ramakrishnan, Rupal; Lavilla-Alonso, Sergio et al. (2014) Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. Cancer Immunol Immunother 63:1009-21
Smyth, Tomoko; Paraiso, Kim H T; Hearn, Keisha et al. (2014) Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models. Mol Cancer Ther 13:2793-804
Haarberg, H Eirik; Smalley, Keiran S M (2014) Resistance to Raf inhibition in cancer. Drug Discov Today Technol 11:27-32
Rebecca, Vito W; Smalley, Keiran S M (2014) Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol 91:417-25
Johnson, Douglas B; Smalley, Keiran S M; Sosman, Jeffrey A (2014) Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. Clin Cancer Res 20:4186-92
Rebecca, Vito W; Alicea, Gretchen M; Paraiso, Kim H T et al. (2014) Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 27:1154-8
Cheng, Fengdong; Lienlaf, Maritza; Perez-Villarroel, Patricio et al. (2014) Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 60:44-53
Rebecca, Vito W; Massaro, Renato R; Fedorenko, Inna V et al. (2014) Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma. Pigment Cell Melanoma Res 27:465-78
Fedorenko, Inna V; Fang, Bin; Koomen, John M et al. (2014) Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res 24:448-53